Compare PFSI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | DNTH |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 2018 | 2018 |
| Metric | PFSI | DNTH |
|---|---|---|
| Price | $92.17 | $87.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $128.11 | $121.00 |
| AVG Volume (30 Days) | 438.1K | ★ 540.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 59.25 | N/A |
| EPS | ★ 9.30 | N/A |
| Revenue | ★ $984,629,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.96 | $29.48 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | ★ 3.05 | N/A |
| 52 Week Low | $82.65 | $16.77 |
| 52 Week High | $160.36 | $96.50 |
| Indicator | PFSI | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 54.40 |
| Support Level | $91.78 | $33.94 |
| Resistance Level | $95.79 | $88.45 |
| Average True Range (ATR) | 2.15 | 3.93 |
| MACD | 0.03 | -1.43 |
| Stochastic Oscillator | 50.21 | 38.75 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.